Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03864614 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,515
- Enrollment target
NCT03864614 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 1,515 participants.
The verdict
NCT03864614, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,515 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
Interventions
- DRUG SAGE-217
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,515 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2023-06-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03864614
The ClinicalTrials.gov registry entry for NCT03864614 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,515 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAGE-217 is the first listed.
NCT03864614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03864614 about?
NCT03864614 is a clinical study titled "A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)". This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
What is the current status of trial NCT03864614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,515 participants. The study started on 2019-02-27. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT03864614?
The interventions under investigation include: SAGE-217 (DRUG).
Who is sponsoring clinical trial NCT03864614?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.